利妥昔单抗、苯达莫司汀和阿糖胞苷序贯维奈克拉治疗老年高危套细胞淋巴瘤(FIL_V-RBAC):一项多中心、单臂、2期研究
FIL_V-RBAC研究在意大利35家机构纳入140例初治套细胞淋巴瘤患者,按高危(54例)或低危(86例)分层治疗。高危患者接受4周期RBAC后序贯固定疗程维奈克拉巩固和维持,2年无进展生存率为60%(95%CI 48-74),中位无进展生存期37个月(95%CI 19-未达到),研究提示加用固定疗程维奈克拉可改善高危患者RBAC的疗效。
要点
- 高危套细胞淋巴瘤患者接受RBAC后序贯维奈克拉,2年无进展生存率为60%(95%CI 48-74)。
- 中位随访45个月,高危组中位无进展生存期为37个月(95%CI 19-未达到)。
- 维奈克拉巩固期间最常见≥3级不良事件为中性粒细胞减少(12/43,28%)。
核心结论
- 据作者所知,这是首个根据风险特征将套细胞淋巴瘤患者分层接受不同治疗的前瞻性研究。
- 研究结果提示,加用固定疗程维奈克拉可改善高危疾病特征患者中RBAC的疗效。
- 研究结果指出在初诊时识别高危疾病患者的重要性。
研究设计与样本
- FIL_V-RBAC为在意大利Fondazione Italiana Linfomi的35家机构开展的多中心、单臂、2期研究,注册号NCT03567876,本文为最终报告。
- 纳入初治、组织学诊断为套细胞淋巴瘤、年龄65岁及以上且根据Fondazione Italiana Linfomi改良综合老年评估为适合的患者,或年龄小于65岁且不适合大剂量化疗、东部肿瘤协作组体能状态评分2分及以下的患者。
- 入组后根据是否存在母细胞样形态、Ki67≥30%、TP53或17p缺失,将患者分为低危或高危疾病。
- 低危患者接受RBAC静脉给药(利妥昔单抗375 mg/m2第1天;苯达莫司汀70 mg/m2第1、2天;阿糖胞苷500 mg/m2第1、2、3天),每4周1次,共6周期。
- 高危患者接受4周期RBAC后序贯固定疗程口服维奈克拉巩固(4个月,800 mg/天)和维持(20个月,400 mg/天)。
主要发现
- 2018年9月10日至2021年7月26日筛查155例患者,其中140例入组并分析研究终点。
- 中位年龄72岁(IQR 69-76),男性107例(76%),女性33例(24%),均为白人。
- 54例(39%)为高危特征(28例[20%]TP53突变,19例[14%]17p缺失,34例[24%]Ki67≥30%,13例[9%]母细胞样形态),86例(61%)为低危特征。
- 中位随访45个月(IQR 40-55)后,高危组2年无进展生存率为60%(95%CI 48-74),中位无进展生存期为37个月(95%CI 19-未达到)。
- 维奈克拉巩固期间最常见≥3级不良事件为中性粒细胞减少(43例中12例[28%]),其次为血小板减少(3例[7%])和皮肤反应(3例[7%])。
临床怎么用
- 作者认为,加用固定疗程维奈克拉可改善高危疾病特征患者中RBAC的疗效。
- 作者指出,在初诊时识别高危疾病患者具有重要意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bendamustine and rituximab combined with intermediate-dose cytarabine (RBAC) is one of the standard initial treatments for older, fit patients with mantle cell lymphoma. We aimed to investigate whether the addition of venetoclax to RBAC would improve progression-free survival in patients with high-risk mantle cell lymphoma. METHODS: FIL_V-RBAC was a multicentre, single-arm, phase 2 study done in 35 institutions of the Fondazione Italiana Linfomi in Italy. Treatment-naive patients with a histological diagnosis of mantle cell lymphoma, aged 65 years or older and fit according to the Fondazione Italiana Linfomi modified comprehensive geriatric assessment (or younger than 65 years and ineligible for high-dose chemotherapy with Eastern Cooperative Oncology Group performance status of 2 or less), were classified after enrolment as having low-risk or high-risk disease, based on the presence of blastoid morphology, Ki67 30% or higher, TP53, or 17p deletion. Patients with a low-risk profile received RBAC intravenously (rituximab 375 mg/m2 and day 1; bendamustine 70 mg/m2 on days 1 and 2; and cytarabine 500 mg/m2 on days 1, 2, and 3) every 4 weeks for 6 cycles. Patients with a high-risk profile received four cycles of RBAC followed by fixed-duration oral venetoclax consolidation (4 months, 800 mg/day) and maintenance (20 months, 400 mg/day). The primary endpoint was 2-year progression-free survival for patients with a high-risk profile who received at least one dose of RBAC. This trial was registered with ClinicalTrials.gov, NCT03567876, and this is the final report. FINDINGS: Between Sept 10, 2018, and July 26, 2021, 155 patients were screened for inclusion, 140 of whom were enrolled and analysed for study endpoints. Median age was 72 (IQR 69-76), 107 (76%) patients were male, 33 (24%) were female, and all were White. 54 (39%) patients had a high-risk profile (28 [20%] with TP53 mutations, 19 [14%] with 17p deletions, 34 [24%] with Ki67 ≥30%, and 13 [9%] with a blastoid morphology) and 86 (61%) had a low-risk profile. After a median follow-up of 45 months (IQR 40-55), the 2-year progression-free survival in the high-risk group was 60% (95% CI 48-74) and the median progression-free survival was 37 months (95% CI 19-not reached). The most frequent grade 3 or worse adverse events during venetoclax consolidation were neutropenia (12 [28%] of 43 patients), followed by thrombocytopenia (three [7%]) and skin reactions (three [7%]). During venetoclax maintenance, the most frequent grade 3 or worse adverse events were neutropenia (seven [19%] of 37 patients), followed by thrombocytopenia (two [5%]) and anaemia (two [5%]). One (1%) of 140 patients had a treatment-related death (tumour lysis syndrome during first induction with RBAC in a patient with a high-risk profile). INTERPRETATION: To our knowledge, this is the first prospective study to stratify patients with mantle cell lymphoma to different treatments according to their risk profile. Our results suggest that the addition of fixed-duration venetoclax improves the performance of RBAC in patients with a high-risk disease profile. Our findings point to the importance of identifying patients with high-risk disease at initial diagnosis. FUNDING: Fondazione Italiana Linfomi-Ente del Terzo Settore, Leukemia and Lymphoma Society, and Ministry of Health, Italy, and AbbVie. TRANSLATION: For the Italian translation of the abstract see Supplementary Materials section.
引用
- Visco C, Tabanelli V, Sacchi MV, et al. Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2025. PMID: 40975105. doi:10.1016/S2352-3026(25)00252-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。